Press Release Archive
-
New Findings Show Sustained Improvement in Employee Quality of Life 18 Months After TrainingNew Findings Show Sustained Improvement in Employee Quality of Life 18 Months After Training2.5-day energy management training was associated with statistically significant improvement in personal purpose, energy levels, and general health 18 months after course
-
Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with IntentJanssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
In two pivotal Phase 3 trials, SPRAVATO®▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ideation with intent compared to comprehensive standard of care alone -
Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of ScienceDr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020
-
Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.Acquisition Advances Its Vision to Make Medical Intervention Smarter, Less Invasive and More Personalized
-
Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care ConferenceJohnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference
-
World Health Organization Recommends the Use of Bedaquiline-Containing Treatment Regimens For All Drug-Resistant Tuberculosis PatientsWorld Health Organization Recommends the Use of Bedaquiline-Containing Treatment Regimens For All Drug-Resistant Tuberculosis Patients
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
-
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple MyelomaDARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone
· Data selected as a Late-Breaking Abstract at ASH 2019 -
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for TransplantDARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant· Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet
· DARZALEX® is the only CD38-directed antibody to show an overall survival benefit in multiple myeloma
· Additionally, follow-up data from the Phase 3 MAIA study showed significant progression-free survival benefit continuing for three years following DARZALEX® treatment